Surgery to remove the primary tumor in women diagnosed with stage IV breast cancer, followed by the standard combination of therapies, adds months to patients’ lives, a new study shows.
“Our findings will change the standard of care for women newly diagnosed with stage IV breast cancer,” says principal investigator Atilla Soran, clinical professor of surgery at the University of Pittsburgh School of Medicine, and a breast surgical oncologist. “We’ve shown that surgery to remove the primary tumor—either through lumpectomy or mastectomy—followed by standard therapy, is beneficial over no surgery.”
Researchers began the trial in 2007, ultimately recruiting a total of 274 women newly diagnosed with stage IV breast cancer from 25 institutions. Half the women received standard therapy, which avoids surgery and includes a combination of chemotherapy, hormonal therapy, and targeted therapy, while the other half first had surgery to remove their primary breast tumor, followed by the standard therapy.
At about 40 months after diagnosis, the women who received the surgery plus standard therapy lived an average of nine months longer than their counterparts who received standard therapy alone.
Nearly 42 percent of the women who received surgery lived to five years after diagnosis, compared with less than 25 percent of the women who did not receive surgery.
The trial also showed that surgery in younger women with less aggressive cancers resulted in longer average survival than in women with more aggressive cancers that had spread to the liver or lungs.
“Our thinking is similar to how you might approach a battle against two enemies,” Soran says. “First you quickly dispatch one army—the primary tumor—leaving you to concentrate all your efforts on battling the second army—any remaining cancer.”
The Turkish Federation of Societies for Breast Diseases funded the work which will be presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
Source: University of Pittsburgh